Esperion combo lowers LDL-C in Phase III for high-risk ASCVD

Esperion Therapeutics Inc. (NASDAQ:ESPR) said its bempedoic acid/ezetimibe combination pill met the primary endpoint of reducing LDL-C in the Phase III 1002-053 trial to treat hypercholesterolemia in high-risk atherosclerotic cardiovascular disease (ASCVD) patients on maximally tolerated statins. The company reiterated its

Read the full 415 word article

User Sign In